436 related articles for article (PubMed ID: 33792945)
21. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
Isaacsson Velho P; Silberstein JL; Markowski MC; Luo J; Lotan TL; Isaacs WB; Antonarakis ES
Prostate; 2018 Apr; 78(5):401-407. PubMed ID: 29368341
[TBL] [Abstract][Full Text] [Related]
22. Germline Mutations in African American Men With Prostate Cancer: Incidence, Implications and Diagnostic Disparities.
Bree KK; Hensley PJ; Pettaway CA
Urology; 2022 May; 163():148-155. PubMed ID: 34453957
[TBL] [Abstract][Full Text] [Related]
23. Ethnic disparities among men with prostate cancer undergoing germline testing.
Kwon DH; Borno HT; Cheng HH; Zhou AY; Small EJ
Urol Oncol; 2020 Mar; 38(3):80.e1-80.e7. PubMed ID: 31630993
[TBL] [Abstract][Full Text] [Related]
24. Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes.
Kohaar I; Zhang X; Tan SH; Nousome D; Babcock K; Ravindranath L; Sukumar G; Mcgrath-Martinez E; Rosenberger J; Alba C; Ali A; Young D; Chen Y; Cullen J; Rosner IL; Sesterhenn IA; Dobi A; Chesnut G; Turner C; Dalgard C; Wilkerson MD; Pollard HB; Srivastava S; Petrovics G
Nat Commun; 2022 Mar; 13(1):1361. PubMed ID: 35292633
[TBL] [Abstract][Full Text] [Related]
25. Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry.
Hurst Z; Liyanarachchi S; He H; Brock P; Sipos J; Nabhan F; Kebebew E; Green P; Cote GJ; Sherman S; Walker CJ; Chang YS; Xue S; Hollingsworth B; Li W; Genutis L; Menq E; de la Chapelle A; Jhiang SM
Thyroid; 2019 Apr; 29(4):530-539. PubMed ID: 30654714
[TBL] [Abstract][Full Text] [Related]
26. Germline BRCA Mutation Rates in Latina Women Presenting for Gynecologic Oncology Care.
Hong L; Gonzalez R; Unternaehrer J; Ioffe Y
Gynecol Obstet Invest; 2020; 85(3):214-221. PubMed ID: 32203957
[TBL] [Abstract][Full Text] [Related]
27. Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion.
Greenberg SE; Hunt TC; Ambrose JP; Lowrance WT; Dechet CB; O'Neil BB; Tward JD
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250421
[TBL] [Abstract][Full Text] [Related]
28. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men.
Bangsi D; Zhou J; Sun Y; Patel NP; Darga LL; Heilbrun LK; Powell IJ; Severson RK; Everson RB
Urol Oncol; 2006; 24(1):21-7. PubMed ID: 16414488
[TBL] [Abstract][Full Text] [Related]
29. Genetically Informed Prostate Cancer Treatment for Metastatic Disease.
Siebert AL; Szymaniak BM; Numan Y; Morgans AK
Urol Clin North Am; 2021 Aug; 48(3):365-371. PubMed ID: 34210491
[TBL] [Abstract][Full Text] [Related]
30. Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer.
Gheybi K; Jiang J; Mutambirwa SBA; Soh PXY; Kote-Jarai Z; Jaratlerdsiri W; Eeles RA; Bornman MSR; Hayes VM
J Natl Compr Canc Netw; 2023 Mar; 21(3):289-296.e3. PubMed ID: 36898365
[TBL] [Abstract][Full Text] [Related]
31. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
[TBL] [Abstract][Full Text] [Related]
32. Genetic Contribution to Metastatic Prostate Cancer.
Sokolova AO; Obeid EI; Cheng HH
Urol Clin North Am; 2021 Aug; 48(3):349-363. PubMed ID: 34210490
[TBL] [Abstract][Full Text] [Related]
33.
Ganaie AA; Beigh FH; Astone M; Ferrari MG; Maqbool R; Umbreen S; Parray AS; Siddique HR; Hussain T; Murugan P; Morrissey C; Koochekpour S; Deng Y; Konety BR; Hoeppner LH; Saleem M
Clin Cancer Res; 2018 Dec; 24(24):6421-6432. PubMed ID: 30087142
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of retesting in patients with previously uninformative cancer genetics evaluations.
Dettwyler SA; Koeppe ES; Jacobs MF; Stoffel EM
Fam Cancer; 2022 Jul; 21(3):375-385. PubMed ID: 34545504
[TBL] [Abstract][Full Text] [Related]
35. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
Nanda R; Schumm LP; Cummings S; Fackenthal JD; Sveen L; Ademuyiwa F; Cobleigh M; Esserman L; Lindor NM; Neuhausen SL; Olopade OI
JAMA; 2005 Oct; 294(15):1925-33. PubMed ID: 16234499
[TBL] [Abstract][Full Text] [Related]
36. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans.
Shook SJ; Beuten J; Torkko KC; Johnson-Pais TL; Troyer DA; Thompson IM; Leach RJ
Clin Cancer Res; 2007 Oct; 13(19):5959-64. PubMed ID: 17908993
[TBL] [Abstract][Full Text] [Related]
37. Inherited DNA-repair gene mutations in African American men with prostate cancer.
Sartor O; Yang S; Ledet E; Moses M; Nicolosi P
Oncotarget; 2020 Jan; 11(4):440-442. PubMed ID: 32064047
[TBL] [Abstract][Full Text] [Related]
38. Germline BLM mutations and metastatic prostate cancer.
Ledet EM; Antonarakis ES; Isaacs WB; Lotan TL; Pritchard C; Sartor AO
Prostate; 2020 Feb; 80(2):235-237. PubMed ID: 31816118
[TBL] [Abstract][Full Text] [Related]
39. Androgen receptor mutations and polymorphisms in African American prostate cancer.
Koochekpour S; Buckles E; Shourideh M; Hu S; Chandra D; Zabaleta J; Attwood K
Int J Biol Sci; 2014; 10(6):643-51. PubMed ID: 24948877
[TBL] [Abstract][Full Text] [Related]
40. African-American men with prostate cancer have larger tumor volume than Caucasian men despite no difference in serum prostate specific antigen.
Fuletra JG; Kamenko A; Ramsey F; Eun DD; Reese AC
Can J Urol; 2018 Feb; 25(1):9193-9198. PubMed ID: 29524974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
